[HTML][HTML] Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
N Grabinski, F Ewald, BT Hofmann, K Staufer… - Molecular cancer, 2012 - Springer
Background Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway,
mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However …
mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However …
[HTML][HTML] Vertical targeting of AKT and mTOR as well as dual targeting of AKT and MEK signaling is synergistic in hepatocellular carcinoma
F Ewald, D Nörz, A Grottke, J Bach… - Journal of …, 2015 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the sixth most common cancer, and the third most
common cause of cancer related death worldwide. The multi-kinase inhibitor Sorafenib …
common cause of cancer related death worldwide. The multi-kinase inhibitor Sorafenib …
Pivotal role of mTOR signaling in hepatocellular carcinoma
BACKGROUND & AIMS: The advent of targeted therapies in hepatocellular carcinoma
(HCC) has underscored the importance of pathway characterization to identify novel …
(HCC) has underscored the importance of pathway characterization to identify novel …
[HTML][HTML] The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy
C Simioni, AM Martelli, A Cani, R Cetin-Atalay… - Oncotarget, 2013 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Advanced or recurrent HCC is frequently resistant to conventional …
malignancies worldwide. Advanced or recurrent HCC is frequently resistant to conventional …
Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer
C Wang, A Cigliano, S Delogu, J Armbruster… - Cell cycle, 2013 - Taylor & Francis
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death
worldwide, with limited treatment options. AKT/mTOR and Ras/MAPK pathways are …
worldwide, with limited treatment options. AKT/mTOR and Ras/MAPK pathways are …
[PDF][PDF] The mTORC2‐Akt1 cascade is crucial for c‐Myc to promote hepatocarcinogenesis in mice and humans
Z Xu, M Xu, P Liu, S Zhang, R Shang, Y Qiao… - …, 2019 - Wiley Online Library
Hepatocellular carcinoma (HCC) is a deadly form of liver cancer with limited treatment
options. The c‐Myc transcription factor is a pivotal player in hepatocarcinogenesis, but the …
options. The c‐Myc transcription factor is a pivotal player in hepatocarcinogenesis, but the …
[HTML][HTML] Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells
JO Kim, KH Kim, IS Song, KS Cheon, OH Kim, SC Lee… - Oncotarget, 2017 - ncbi.nlm.nih.gov
There is lots of evidence to support the critical involvement of mTOR signaling in the
carcinogenesis of hepatocellular carcinoma (HCC). However, it has not been determined …
carcinogenesis of hepatocellular carcinoma (HCC). However, it has not been determined …
[HTML][HTML] Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)-a correlative study to explore potential biomarkers for …
W Yeo, SL Chan, FKF Mo, CM Chu, JWY Hui… - BMC cancer, 2015 - Springer
Abstract Background The oncogenic PI3K/Akt/mTOR pathway is frequently activated in HCC.
Data on the mTOR inhibitor, temsirolimus, is limited in HCC patients with concomitant …
Data on the mTOR inhibitor, temsirolimus, is limited in HCC patients with concomitant …
[HTML][HTML] Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends
MS Matter, T Decaens, JB Andersen… - Journal of …, 2014 - Elsevier
Mechanistic target of rapamycin (mTOR) regulates cell growth, metabolism and aging in
response to nutrients, cellular energy stage and growth factors. mTOR is frequently up …
response to nutrients, cellular energy stage and growth factors. mTOR is frequently up …
[HTML][HTML] Activation of mTOR signaling pathway in hepatocellular carcinoma
G Ferrín, M Guerrero, V Amado… - International Journal of …, 2020 - mdpi.com
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and occurs mainly
in patients with liver cirrhosis. The mammalian target of rapamycin (mTOR) signaling …
in patients with liver cirrhosis. The mammalian target of rapamycin (mTOR) signaling …